ERIS Lifesciences Ltd (ERIS)

Eris Lifesciences Limited was incorporated in 2007 and is engaged in manufacturing, distributing and marketing of branded pharmaceutical products, having presence in high growth chronic, sub-chronic and acute therapeutic areas. It has a portfolio of 112 Mother Brands across therapy areas and 5 subsidiaries, 4 of which are wholly owned subsidiaries. The company has made two acquisitions - UTH Healthcare Ltd for Rs 129 million for its product portfolio in 2017 and Indian branded formulations business Strides for Rs 5000 crore in 2017. It made its debut in secondary equity market in 2017 and in FY 2018 capital expenditure amounted to Rs 242.69 million and Rs 5061.52 million was paid towards business acquisition. In FY 2019 the company expanded its operations by constructing new softgel facility, extended facility for supplements and nutraceuticals, and added Zomelis products in its portfolio. In 2020, Kinedex became wholly owned subsidiary and the company launched new business divisions. In FY21 it launched Gluxit in SGLT2 segment, Eritel and LNBloc maintained ranks in their respective segments, developed Bricet and fortified portfolio with the launch of ZACD. In FY22 it acquired 100 stake in Oaknet Healthcare Ltd worth Rs 6500 million and launched human insulin through its subsidiary Eris M.J. Biopharm Ltd and Xsulin in vials and cartridges.

Share Price: ₹1048.70 per share as on 24 Jul, 2024 04:01 PM
Market Capitalisation: ₹14,115.06Cr as of today
Revenue: ₹547.27Cr as on March 2024 (Q1 24)
Net Profit: ₹79.63Cr as on March 2024 (Q1 24)
Listing date: 29 Jun, 2017
Chairperson Name: Amit Indubhushan Bakshi